Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Caspofungin pharmacokinetics and dose optimization in critically ill ICU patients with suspected invasive candidiasis
NL-OMON40105Phase 4Active, not recruiting
- Sponsor
- University Medical Center Groningen
- Start
- Dec 2013
- Modality
- Antimicrobial Peptides → Native Peptides → Peptides, Cyclic Peptides → Modified Peptides → Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of caspofungin in invasive candidiasis and invasive mycoses, sponsored by University Medical Center Groningen. Primary endpoint: Optimal dosage of caspofungin in relation to adequate exposure. Started Dec 2013; status: active, not recruiting.
02
Drugs
caspofungin
03
Conditions
invasive candidiasisinvasive mycoses
Beyond the preview
Go deeper on NL-OMON40105.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON40105.